Patents by Inventor Catherine Y. Spong

Catherine Y. Spong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Orally active peptides that prevent cell damage and death
    Patent number: 8017578
    Abstract: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: September 13, 2011
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Ramot at Tel-Aviv University Ltd.
    Inventors: Douglas Brenneman, Illana Gozes, Catherine Y. Spong, Albert Pinhasov, Eliezer Giladi
  • Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
    Patent number: 7863247
    Abstract: The invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide (e.g, ADNF I polypeptides, ADNF III polypeptides, or mixtures of ADNF I and ADNF III polypeptides). In one embodiment, the present invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a mixture of ADNF I and ADNF III polypeptides. The present invention further relates to methods for reducing neuronal cell death by contacting neuronal cells with a mixture of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a mixture of ADNF I and ADNF III polypeptides.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: January 4, 2011
    Assignee: Ramot-University Authority for Applied Research and Development Ltd.
    Inventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Merav Bassan, Rachel Zamostiano
  • NEUROTROPHIC COMPONENTS OF THE ADNF I COMPLEX
    Publication number: 20090247457
    Abstract: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.
    Type: Application
    Filed: August 25, 2008
    Publication date: October 1, 2009
    Applicants: SECRETARY OF THE DEPTARTMENT OF HEALTH AND HUMAN SERVICES, RAMOT AT TEL-AVIV UNIVERSITY
    Inventors: DOUGLAS E. BRENNEMAN, RAQUEL CASTELLON, CATHERINE Y. SPONG, JANET M. HAUSER, IIIANA GOZES
  • USE OF ACTIVITY DEPENDENT NEUROTROPHIC FACTOR FOR ENHANCING LEARNING AND MEMORY: PRE-AND POST-NATAL ADMINISTRATION
    Publication number: 20090203615
    Abstract: The present invention provides methods for improving performance (e.g., learning and/or memory) using ADNF polypeptides, by treating the subject prenatally or postnatally with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to improve postnatal learning and/or memory of the subject.
    Type: Application
    Filed: August 25, 2008
    Publication date: August 13, 2009
    Applicants: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT, DEPARTMENT OF HEALTH AND HUMAN SERVICES, RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: CATHERINE Y. SPONG, DOUGLAS BRENNEMAN, IIIANA GOZES
  • Neurothrophic components of the ADNF I complex
    Patent number: 7427590
    Abstract: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: September 23, 2008
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Ramot at Tel-Aviv University, Ltd.
    Inventors: Douglas E. Brenneman, Raquel Castellon, Catherine Y. Spong, Janet M. Hauser, Illana Gozes
  • Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory
    Patent number: 7427598
    Abstract: The present invention provides methods for improving performance (e.g. learning and/or memory) using (ADNF) polypeptides, by treating the subject prenatally or postnatally with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to improve postnatal learning and/or memory of the subject.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: September 23, 2008
    Assignees: The United States of Americas as represented by the Secretary of the Department of Health and Human Services, Ramot at Tel-Aviv University, Ltd.
    Inventors: Catherine Y. Spong, Douglas Brenneman, Illana Gozes
  • ORALLY ACTIVE PEPTIDES THAT PREVENT CELL DAMAGE AND DEATH
    Publication number: 20080194488
    Abstract: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.
    Type: Application
    Filed: April 14, 2008
    Publication date: August 14, 2008
    Applicants: National Institute of Health, Ramot at Tel-Aviv University Ltd.
    Inventors: Illana Gozes, Albert Pinhasov, Eliezer Giladi, Douglas E. Brenneman, Catherine Y. Spong
  • Orally active peptides that prevent cell damage and death
    Patent number: 7384908
    Abstract: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: June 10, 2008
    Assignee: National Institute of Health
    Inventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Albert Pinhasov, Eliezer Giladi
  • Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
    Patent number: 6933277
    Abstract: This invention relates to a method for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide. In particular, the present invention relates to a method of reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a combination of ADNF I and ADNF III polypeptides. The present invention further relates to a method for reducing neuronal cell death by contacting neuronal cells with a combination of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a combination of ADNF I and ADNF III polypeptides.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: August 23, 2005
    Assignees: The United States of America as represented by the Department of Health and Human Services, Ramot University Authority for Applied Research and Industrial Development, Ltd.
    Inventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Merav Bassan, Rachel Zamostiano
  • Use of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory:pre-and post-natal administration
    Publication number: 20040048801
    Abstract: The present invention provides methods for improving performance (e.g. learning and/or memory) using ADNF polypeptides, by treating the subject prenatally or postnatally with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to improve postnatal learning and/or memory of the subject.
    Type: Application
    Filed: November 27, 2002
    Publication date: March 11, 2004
    Inventors: Catherine Y Spong, Douglas Brenneman, Illana Gozes
  • PREVENTION OF FETAL ALCOHOL SYNDROME AND NEURONAL CELL DEATH WITH ADNF POLYPEPTIDES
    Publication number: 20020111301
    Abstract: This invention relates to a method for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide. In particular, the present invention relates to a method of reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a combination of ADNF I and ADNF III polypeptides. The present invention further relates to a method for reducing neuronal cell death by contacting neuronal cells with a combination of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a combination of ADNF I and ADNF III polypeptides.
    Type: Application
    Filed: March 12, 1999
    Publication date: August 15, 2002
    Inventors: DOUGLAS E. BRENNEMAN, CATHERINE Y. SPONG, ILLANA GOZES, MERAV BASSAN, RACHEL ZAMOSTIANO